STAAR Surgical Q4 net sales up 19% to $76.3M; ICL sales +22%; FY2024 outlook $335-340M

STAAR SURGICAL CO

2023-FY EPS reported $0.43 revenue$322,415,000

Q4 net sales $76.3M (+19% YoY), ICL sales $74.6M (+22%), ICL units +19%.
Q4 net income $7.8M ($0.16 EPS) vs $6.8M ($0.14 EPS); gross margin 79.6% vs 77.7%.
FY2023 net sales $322.4M (+13%), net income $21.3M ($0.43 EPS) vs $39.7M ($0.80 EPS).
Cash, cash equivalents and investments $232.4M, no debt; FY2024 net sales outlook $335-340M.
China ICL sales grew 30% in Q4; EMEA up 18%; company affirms FY2024 sales outlook.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STAAR SURGICAL CO updated its the quarter and year ended December 29, 2023 guidance (reaffirmed).

Period: the quarter and year ended December 29, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 26, 2024, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter and year ended December 29, 2023, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0000950170-24-020126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.